Q-omics provides the consensus-scored DCT profile across patient tissues and cancer cell-line models. DCT expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DCT is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, DCT RNA expression shows 14,594 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, BLCA, and THYM as cancer lineages where DCT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCT survival associations across molecular data types. DCT RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCT RNA expression–survival associations across cancer types. High DCT expression shows unfavorable associations in KIRP, OV, SCLC, ESCA, HNSC and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify KIRP as the clearest survival context for DCT RNA expression.
This table summarizes DCT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DCT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCT shows lower tumor expression in BLCA, HNSC, BRCA, UCEC, KICH and THCA. The BLCA box plot shows higher DCT RNA expression in normal versus tumor tissue (log2 FC = −0.180, t-test p = .003).
This table shows molecular features associated with DCT in patient tissues and cancer cell lines. In patient samples, DCT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DCT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
